Accelerate Diagnostics Stock Forecast, Price & News

-0.36 (-4.00 %)
(As of 06/16/2021 10:33 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,407 shs
Average Volume414,706 shs
Market Capitalization$526.81 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Accelerate Diagnostics logo

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.65 out of 5 stars

Medical Sector

386th out of 2,100 stocks

Analytical Instruments Industry

9th out of 32 stocks

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

Is Accelerate Diagnostics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than Accelerate Diagnostics?

Wall Street analysts have given Accelerate Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Accelerate Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Accelerate Diagnostics

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its earnings results on Thursday, May, 6th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.08. The medical research company earned $2.52 million during the quarter, compared to analysts' expectations of $3.55 million.
View Accelerate Diagnostics' earnings history

How has Accelerate Diagnostics' stock been impacted by COVID-19?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXDX shares have decreased by 17.3% and is now trading at $8.77.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AXDX?

3 brokerages have issued 1-year target prices for Accelerate Diagnostics' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Accelerate Diagnostics' stock price to reach $14.50 in the next year. This suggests a possible upside of 65.3% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:
  • Mr. Jack Phillips, CEO, Pres & Director (Age 55, Pay $619.96k)
  • Mr. Steve Reichling, CFO, Chief Accounting Officer & Sec. (Age 43, Pay $324.08k)
  • Mr. Lawrence Mehren, Advisor (Age 55, Pay $293.27k)
  • Mr. Ron Price, Chief Commercial Officer of Americas (Age 57, Pay $225.23k)
  • Laura Pierson, Investor Relations Officer
  • Mr. Michael Bridge, Sr. VP & Gen. Counsel
  • Ms. Gretchen Strohminger, Sr. VP and Head of HR & Culture
  • Ms. Constance Bridges, Sr. VP and Head of Regulatory & Quality
  • Mr. Cherif Bousselham, Sr. VP & Head of Sales - EMEA
  • Ms. Laura Costa, Sr. VP & Head of Global Customer Support

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Oracle Investment Management Inc. (6.19%), BlackRock Inc. (3.87%), Birchview Capital LP (3.63%), Chicago Capital LLC (2.60%), Griffin Asset Management Inc. (2.22%) and Cannell Peter B & Co. Inc. (1.79%). Company insiders that own Accelerate Diagnostics stock include Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics

Which major investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Griffin Asset Management Inc., Renaissance Technologies LLC, Morgan Stanley, Tudor Investment Corp Et Al, Selkirk Management LLC, GSA Capital Partners LLP, Oracle Investment Management Inc., and D. E. Shaw & Co. Inc.. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Jack Phillips, Romney Humphries, Ron Price, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or view top insider-selling stocks.

Which major investors are buying Accelerate Diagnostics stock?

AXDX stock was purchased by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Rafferty Asset Management LLC, Graham Capital Management L.P., BlackRock Inc., Geode Capital Management LLC, Millennium Management LLC, Birchview Capital LP, and Algert Global LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $8.77.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics has a market capitalization of $535.36 million and generates $11.16 million in revenue each year. The medical research company earns $-78,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

Accelerate Diagnostics employs 224 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is

Where are Accelerate Diagnostics' headquarters?

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.